ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 490,28
0,51%
Dow Jones
42 635,20
0,00%
DAX
20 317,10
0,00%
Brent Oil
76,945
1,26%
Bitcoin
92 027,71
-3,19%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. New River Pharmaceuticals (MM) (NRPH)

  7. New River Pharmaceuticals (MM) (NRPH) Actualités

NRPH

New River (NRPH)

New River Pharmaceuticals (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NRPH
DateHeureSourceTitreSymboleSociété
18/04/200722h41PR Newswire (US)HealthShares(TM) Announces Changes to the HealthShares(TM) Neuroscience and Composite IndicesNASDAQ:NRPHNew River Pharmaceuticals (MM)
03/04/200715h00PR Newswire (US)New River Pharmaceuticals Inc. Announces Convertibility of 3.50% Convertible Subordinated Notes Due 2013NASDAQ:NRPHNew River Pharmaceuticals (MM)
19/03/200715h00PR Newswire (US)New River Announces Expiration of Hart-Scott-Rodino Waiting PeriodNASDAQ:NRPHNew River Pharmaceuticals (MM)
14/03/200700h30PR Newswire (US)New River Pharmaceuticals Announces Year-End ResultsNASDAQ:NRPHNew River Pharmaceuticals (MM)
23/02/200723h07PR Newswire (US)Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only Stimulant Prodrug VYVANSE(TM) (lisdexamfetamineNASDAQ:NRPHNew River Pharmaceuticals (MM)
20/02/200712h00PR Newswire (US)New River Pharmaceuticals to be Acquired by Shire plc for $64 per ShareNASDAQ:NRPHNew River Pharmaceuticals (MM)
05/02/200716h18PR Newswire (US)New River Pharmaceuticals to Present at 2007 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical ConferenceNASDAQ:NRPHNew River Pharmaceuticals (MM)
25/01/200721h01PR Newswire (US)James Shaffer Joins New River Pharmaceuticals as Vice President, Sales and MarketingNASDAQ:NRPHNew River Pharmaceuticals (MM)
22/12/200605h34PR Newswire (US)New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment ofNASDAQ:NRPHNew River Pharmaceuticals (MM)
07/11/200623h22PR Newswire (US)New River Pharmaceuticals Announces Third Quarter 2006 ResultsNASDAQ:NRPHNew River Pharmaceuticals (MM)
30/10/200615h00PR Newswire (US)Interim Results of a Phase III Trial of Lisdexamfetamine Dimesylate (NRP104/LDX) in ADHD Presented at Major Scientific MeetingNASDAQ:NRPHNew River Pharmaceuticals (MM)
13/10/200615h45PR Newswire (US)New River Pharmaceuticals Conducts End-of-Phase II Meeting with FDA for NRP290NASDAQ:NRPHNew River Pharmaceuticals (MM)
07/10/200603h25PR Newswire (US)FDA Issues Approvable Letter for NRP104 (lisdexamfetamine dimesylate) for the Treatment of ADHDNASDAQ:NRPHNew River Pharmaceuticals (MM)
07/10/200603h23PR Newswire (US)New River Pharmaceuticals Inc. Receives Approvable Letter for NRP104NASDAQ:NRPHNew River Pharmaceuticals (MM)
03/10/200623h20PR Newswire (US)Dr. Garen Manvelian Joins New River Pharmaceuticals as Chief Medical OfficerNASDAQ:NRPHNew River Pharmaceuticals (MM)
12/09/200621h00PR Newswire (US)New River Pharmaceuticals Inc. Meets Enrollment in NRP104 Adult Phase III StudyNASDAQ:NRPHNew River Pharmaceuticals (MM)
08/09/200623h38PR Newswire (US)New River Pharmaceuticals to Present at the Bear Stearns 19th Annual Healthcare ConferenceNASDAQ:NRPHNew River Pharmaceuticals (MM)
18/08/200600h03PR Newswire (US)New River Pharmaceuticals Names Dr. Samir Roy Vice President, Formulation and ManufacturingNASDAQ:NRPHNew River Pharmaceuticals (MM)
08/08/200623h46PR Newswire (US)New River Pharmaceuticals Announces Second Quarter 2006 ResultsNASDAQ:NRPHNew River Pharmaceuticals (MM)
25/07/200622h58PR Newswire (US)New River Pharmaceuticals Announces Exercise of Co-Promotion Option in the U.S. for NRP104NASDAQ:NRPHNew River Pharmaceuticals (MM)
25/07/200618h57PR Newswire (US)New River Pharmaceuticals Closes Sale of $135,000,000 Convertible Subordinated NotesNASDAQ:NRPHNew River Pharmaceuticals (MM)
24/07/200615h41Business WireAMRI Announces Long-Term Manufacturing Agreement with New River PharmaceuticalsNASDAQ:NRPHNew River Pharmaceuticals (MM)
20/07/200603h06PR Newswire (US)New River Pharmaceuticals Prices $125 Million Convertible Subordinated Notes; Company to Repurchase Up to $51 million in CommonNASDAQ:NRPHNew River Pharmaceuticals (MM)
18/07/200623h26PR Newswire (US)New River Pharmaceuticals Announces Proposal to Offer $125 Million Convertible Subordinated Notes; Company to Repurchase up toNASDAQ:NRPHNew River Pharmaceuticals (MM)
30/06/200616h31PR Newswire (US)New River Pharmaceuticals Announces Filing of Investigational New Drug Application for NRP409NASDAQ:NRPHNew River Pharmaceuticals (MM)
23/06/200618h52PR Newswire (US)New River Pharmaceuticals to Host Conference Call on A01, A02 and A03 Clinical Abuse Liability Studies of NRP104NASDAQ:NRPHNew River Pharmaceuticals (MM)
20/06/200623h30PR Newswire (US)New River Pharmaceuticals Provides Detail on A02 Clinical Abuse Liability Study of NRP104NASDAQ:NRPHNew River Pharmaceuticals (MM)
18/06/200623h45PR Newswire (US)New River Pharmaceuticals Provides Detail on A01 Clinical Abuse Liability Study and Announces Results from A03 StudyNASDAQ:NRPHNew River Pharmaceuticals (MM)
14/06/200615h01PR Newswire (US)New River Pharmaceuticals to Present Results from NRP104 Abuse Liability StudiesNASDAQ:NRPHNew River Pharmaceuticals (MM)
31/05/200600h33PR Newswire (US)New River Pharmaceuticals to Present at the Friedman Billings Ramsey 2006 Growth Investor ConferenceNASDAQ:NRPHNew River Pharmaceuticals (MM)
 Showing the most relevant articles for your search:NASDAQ:NRPH

Dernières Valeurs Consultées

EU
ORA
Orange
EU
PX4
SBF 120
EU
EN
Bouygues
EU
HO
Thales
EU
PX1
CAC 40
NASDAQ
MSFT
Microsoft
NYSE
JPM
JP Morgan Chase
SPI
SP500
S&P 500
NASDAQ
GOOGL
Alphabet
COIN
XRPUSD
Ripple
COIN
ADAUSD
Cardano
NYSE
DIS
Walt Disney
FTSE
UKX
FTSE 100
EU
CAP
Capgemini
EU
BEL20
Bel 20
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés